Planegg

Researchers are evaluating the retention rates of two treatments, Upadacitinib (UPA) and tumor necrosis factor inhibitors (TNFi), in adults with moderate to severe active rheumatoid arthritis (RA). The study is observational, conducted in Germany, and aims to compare how long patients stay on each treatment under real-world conditions according to local labels and standard care. About 678 participants will be enrolled across approximately 80 sites in Germany. Participants will have been prescribed UPA or TNFi independently of the study, following approved labels and local regulations. The study will observe participants receiving either UPA or TNFi therapy over a period of up to 24 months. Participants will be followed for up to 24 months to assess treatment retention. Researchers will monitor how long participants remain on their prescribed treatment and collect related clinical data. The total study duration, including recruitment and follow-up, is expected to last about 48 months.

Axial spondyloarthritis (axSpA) is an immune-related inflammatory disease mainly affecting the spine, causing chronic back pain and significantly impacting quality of life with symptoms like sleep problems, social isolation, and emotional distress. This research is evaluating the real-world effectiveness of the drug upadacitinib in controlling disease activity and managing pain in adults with active axSpA in Germany. Participants will receive oral upadacitinib tablets as prescribed by their doctors before joining the study, following local guidelines on dosage and treatment. The study will last about 52 weeks, during which participants will continue their prescribed treatment and attend regular medical visits as part of routine care. Throughout the study, researchers will monitor disease activity and treatment effects using medical assessments, side effect checks, and questionnaires. The main focus is on how many participants achieve and maintain low disease activity scores over 24 and 52 weeks, assessing both clinical and patient-reported outcomes related to pain and disease burden.

Psoriatic arthritis (PsA) is a type of arthritis that causes joint swelling and stiffness and is often seen in people with the skin condition psoriasis. It results from an overactive immune system attacking healthy tissue. This research aims to describe the long-term use and effectiveness of risankizumab (RZB) compared to other advanced treatments for managing PsA in everyday clinical care. The study is not conducted in the United States but will take place in about 15 countries and include between 900 and 1200 adult participants. Participants will be assigned in a 2 to 1 ratio to receive either risankizumab or other advanced therapeutic agents. The treatments will be given following usual medical guidelines, including approved dosing and indications, as determined by local regulations and professional standards. All study visits will occur during routine clinical care with no extra burden on participants. Participants will be followed and monitored for 24 months to observe treatment persistence. During the study, participants will continue their regular clinical visits without additional procedures or tests required by the study. Researchers will measure how many participants continue their prescribed treatment over the 24-month period. The study focuses on real-world treatment patterns and outcomes in patients with active PsA who have previously shown an inadequate response or intolerance to certain medications. Safety monitoring will align with routine clinical practice throughout the study duration.

Researchers are collecting real-world data on advanced prostate cancer (APC) imaging through a European registry called the RING study. This study evaluates the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, compared to conventional imaging methods in detecting and monitoring prostate cancer. The study focuses on men aged 18 or older with confirmed prostate cancer who require imaging to check for metastases either at diagnosis or after relapse. Participants will receive imaging according to local protocols and guidelines without any experimental treatments. Imaging may include conventional methods, NGI, or a combination of both, with decisions on imaging and treatment following routine clinical practice. The study includes a cross-sectional observation phase to assess imaging benefits and management impact, and a longitudinal phase to evaluate survival outcomes and prognostic factors related to treatment response and disease progression. During the study, data will be gathered from medical records, including patient demographics, medical history, tumor characteristics, and imaging results. Researchers will monitor the proportion of patients needing different imaging types and how imaging results influence treatment decisions within 4 to 6 weeks. The study aims to help doctors understand the best use of NGI in clinical care and its effect on patient outcomes, with no upper age limit for participants and ongoing follow-up to assess survival and disease progression.

Researchers are evaluating the real-world effects of subcutaneous anifrolumab treatment in adults with systemic lupus erythematosus (SLE) who have not previously used anifrolumab. This non-interventional, prospective, multicenter study aims to assess disease activity, patient quality of life, medication use, flares, and organ damage over a 24-month period in routine clinical care settings. Participants will receive subcutaneous anifrolumab according to European prescribing guidelines, with treatment decisions made independently of the study. This observational study does not involve additional interventions but follows patients receiving this therapy as part of their regular care. During the 24-month observation, participants will undergo clinical evaluations and report outcomes related to disease activity, remission status, quality of life, medication patterns, and organ damage progression. Researchers will measure the proportion of patients achieving remission according to the DORIS criteria at 24 months, alongside monitoring flares and other important clinical outcomes.